WO2017182641A1 - Bilayer tablet formulations of montelukast and rupatadine - Google Patents
Bilayer tablet formulations of montelukast and rupatadine Download PDFInfo
- Publication number
- WO2017182641A1 WO2017182641A1 PCT/EP2017/059538 EP2017059538W WO2017182641A1 WO 2017182641 A1 WO2017182641 A1 WO 2017182641A1 EP 2017059538 W EP2017059538 W EP 2017059538W WO 2017182641 A1 WO2017182641 A1 WO 2017182641A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- layer
- sodium
- bilayer tablet
- tablet formulation
- formulation according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Definitions
- the present invention relates to a bilayer tablet formulation comprising montelukast sodium and rupatadine fumarate.
- Montelukast sodium has one asymmetric center and is the R-isomer. A crystalline and an amorphous form are known. Montelukast sodium is a leukotriene receptor antagonist approved for the prophylaxis and chronic treatment of asthma.
- the chemical name of montelukast is [R-(E)]-1 -[[[1 -[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1 -hydroxy-1 - methylethyl)-phenyl]propyl]thio]methyl] cyclopropane acetic acid mono sodium salt and has the structure shown in the following formula I. It works by blocking the action of substances in the body that cause the symptoms of asthma and allergic rhinitis. It is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma.
- Rupatadine is a second generation antihistamine and PAF (Platelet-activating factor) antagonist used to treat allergies and is marketed under several trade names such as Rupafin, Alergoliber, Rinialer, Pafinur, Rupax and Ralif. Rupatadine fumarate has been approved for the treatment of allergic rhinitis and chronic urticaria in adults and children over 12 years.
- the defined daily dose (DDD) is 10 mg orally.
- rupatadine fumarate 8-Chloro-6,1 1 -dihydro-1 1 -[1 -[(5-methyl-3- pyridyl)methyl]-4-piperidylidene]-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine fumarate and has the structure shown in the following formula II.
- Rupatadine fumarate Rupatadine is first disclosed in US6803468 (Ranbaxy Laboratories Limited) and there are several patent applications describing, its process and other salt forms.
- capsule formulations including montelukast or rupatadine alone or may be in combination.
- a capsule formulation is less effective than a tablet combination and this may cause compatibility and stability problems and moreover dissolution problems of active drug substances.
- a bilayer tablet formulation has been provided to prevent the direct contact of active drug substances.
- the main object of the present invention is to obtain a bilayer tablet formulation comprising a stable and compatible combination of montelukast sodium in first layer and rupatadine fumarate in second layer with a desired dissolution of active drug substances separately.
- the present invention is aimed to obtain a bilayer tablet formulation to prevent an interaction of active drug substances, therefore the incompatibility problem of these agents is eliminated and efficient and desired dissolution and stability are obtained.
- the bilayer tablet formulation of the present invention comprises 3.00 to 15.00 % by weight montelukast sodium as active drug substance in the first layer and comprises 5.00 to 20.00 % by weight rupatadine fumarate as active drug substance in the second layer.
- the bilayer tablet formulation comprises at least one disintegrant.
- the disintegrant is selected from the group comprising croscarmellose sodium, pregelatinized starch, crospovidone, sodium starch glycolate, low- substituted hydroxpropyl cellulose, polyvinylpyrrolidone (K - 30), hydroxylpropyl methyl cellulose, carboxy methyl cellulose calcium, sodium carboxy methyl cellulose, magnesium aluminum silica, sodium dodecyl sulphate, calcium silicate or mixtures thereof.
- the disintegrant is croscarmellose sodium or pregelatinized starch or mixtures thereof.
- the disintegrant is croscarmellose sodium in first layer and pregelatinized starch in second layer. Due to the use of different disintegrants separately in the layers, the efficient and desired dissolution of both active drug substances are achieved rapidly. Disintegrants give advantages to formulation in terms of binding strength to the layers. With the synergistic effect of disintegrants used in layers separately comprising active drug substances, layers adhere to each other and robust bilayer tablet with desired dissolution has been achieved. Disintegrants used in this present invention are croscarmellose sodium in first layer and pregelatinized starch in second layer.
- the weight ratio (w/w) of croscarmellose sodium in first layer to pregelatinized starch in second layer is between 0.1 and 1 .0.
- the weight ratio (w/w) is 0.5 - 0.7.
- the bilayer tablet of the present invention further comprises at least one excipient.
- the excipients are selected from the group comprising binders, fillers, lubricants and coloring agents or mixtures thereof.
- Suitable binders may include but not limited to hydroxylpropyl cellulose (Klucel LF), hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, sugars, glycose syrups, natural gums, guar gum, tragachanti gum, gelatins, pullulan, agar, alginate, sodium algynates, glycyrrhizin, polymetacrylates, collagen, alginate, sodium alginate, hyaluronic acid, pectin, carrageenan, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, benthonite, laponite, cetostearyl alcohol, polyoxyethylene-alkyl ethers, acacia mucilage, polydextrose, polyethylene oxide, xylitol, sucrose stearate or mixtures thereof.
- Suitable fillers may include, but not limited to microcrystalline cellulose (pH 101 , pH 102), lactose monohydrate, starch, mannitol, dibasic calcium phosphate, tribasic calcium di L t jp aanea y
- the filler is microcrystalline cellulose (pH 101).
- Suitable lubricants may include but not limited to magnesium stearate, sodium stearyl fumarate, polyethylene glycol, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, polyethylene glycol, paraffin or mixtures thereof.
- the lubricant is magnesium stearate.
- Suitable coloring agents may include but not limited to yellow iron oxide, Curcumin, Carmine, Indigo Carmine, Chlorophy II, Helindone pink CN, Diiodofluorescein or mixtures thereof.
- the coloring agent is yellow iron oxide.
- hydroxypropyl cellulose 1.00-5.00
- microcrystalline cellulose (PH 101) 30.00-60.00
- Montelukast Layer montelukast sodium, hydroxypropyl cellulose (Klucel LF), microcrystalline cellulose (PH 101 ), lactose monohydrate and half amount of croscarmellose sodium are taken into container. Powder mixture is spray-granulated with pure water. The mixture is dried. The rest of the croscarmellose sodium is added to this mixture, and mixed. Then, magnesium stearate is added to this mixture and mixed.
- Rupatadine layer rupatadine fumarate, prejelatinized starch, microcrystalline cellulose (PH 101 ), lactose monohydrate and yellow iron oxide are taken into collete and powder mixture is wet granulated with pure water. Then, the mixture is sieved and dried in fluid-bed dryer. Then, the mixture is sieved again. Magnesium stareate is added and mixed again. Two powder mixtures, are put into tableting machine separately to form bilayer tablets.
- Example 1 The bilayer tablet formulation of this present invention (Example 1 ), was tested by its dissolution profile in 0.5% solution of sodium dodecyl sulphate and at 37 ⁇ ⁇ using a USP apparatus II method in 900 ml_, rotating at 75 rpm against the reference product which is mentioned below as conventional (one layer) tablet or capsule form. The results are shown below in Table 1 .
- Table 1 Dissolution profile test results (%)
- Reference product* in one layer tablet or in capsule form: montelukast sodium , rupatadine fumarate, hydroxpropyl cellulose (Klucel LF), microcrystalline cellulose (pH101 ), lactose monohydrate, croscarmellose sodium and magnesium stearate.
- the amount of the ingredients are same with the amounts given in example 1 , in montelukast layer
- the dissolution and bioavailbilty of montelukast is significanti decreased.
- they are formulated separately in a bilayer formulation the amounts are increased.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a bilayer tablet formulation comprising montelukast sodium and rupatadine fumarate.
Description
BILAYER TABLET FORMULATIONS OF MONTELUKAST AND RUPATADINE
Field of Invention
The present invention relates to a bilayer tablet formulation comprising montelukast sodium and rupatadine fumarate.
Background of Invention
Montelukast sodium has one asymmetric center and is the R-isomer. A crystalline and an amorphous form are known. Montelukast sodium is a leukotriene receptor antagonist approved for the prophylaxis and chronic treatment of asthma. The chemical name of montelukast is [R-(E)]-1 -[[[1 -[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1 -hydroxy-1 - methylethyl)-phenyl]propyl]thio]methyl] cyclopropane acetic acid mono sodium salt and has the structure shown in the following formula I. It works by blocking the action of substances in the body that cause the symptoms of asthma and allergic rhinitis. It is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma.
Formula I : Montelukast sodium
In patent W09716173, tablet formulation of montelukast sodium has been disclosed. It also exists in the market as tablet, chewable tablet and oral granule under the brand name of SINGULAIR® in U.S.
Rupatadine is a second generation antihistamine and PAF (Platelet-activating factor) antagonist used to treat allergies and is marketed under several trade names such as Rupafin, Alergoliber, Rinialer, Pafinur, Rupax and Ralif.
Rupatadine fumarate has been approved for the treatment of allergic rhinitis and chronic urticaria in adults and children over 12 years. The defined daily dose (DDD) is 10 mg orally. The chemical name of rupatadine fumarate is 8-Chloro-6,1 1 -dihydro-1 1 -[1 -[(5-methyl-3- pyridyl)methyl]-4-piperidylidene]-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine fumarate and has the structure shown in the following formula II.
Formula II : Rupatadine fumarate Rupatadine is first disclosed in US6803468 (Ranbaxy Laboratories Limited) and there are several patent applications describing, its process and other salt forms.
In prior art, there may have some capsule formulations including montelukast or rupatadine alone or may be in combination. However, a capsule formulation is less effective than a tablet combination and this may cause compatibility and stability problems and moreover dissolution problems of active drug substances.
Thus, there is no combination of montelukast sodium with rupatadine fumarate especially in tablet form in prior art.
It has also been found that the combination of rupatadine and montelukast is more effective compared to rupatadine alone in the control of allergic rhinitis symptoms.
In addition, instead of one per se use, combining more than one molecule in one dosage form increases the patients' quality of life and patients' compliance. Considering all these, combinations of montelukast and rupatadine in a suitable pharmaceutical dosage formulation such as a bilayer tablet formulation is needed in the art. However, there are many challenges
while combining two or more molecules in a tablet such as compatibility, dissolution and stability problems.
In this invention, to overcome these problems mentioned above, a bilayer tablet formulation of montelukast and rupatadine has been developed.
In further, in order to overcome stability and especially dissolution problems of active drug substances, a bilayer tablet formulation has been provided to prevent the direct contact of active drug substances.
Description of the invention
The main object of the present invention is to obtain a bilayer tablet formulation comprising a stable and compatible combination of montelukast sodium in first layer and rupatadine fumarate in second layer with a desired dissolution of active drug substances separately.
According to this embodiment, the present invention is aimed to obtain a bilayer tablet formulation to prevent an interaction of active drug substances, therefore the incompatibility problem of these agents is eliminated and efficient and desired dissolution and stability are obtained.
In order to combine two different molecules in one dosage form, molecules should be compatible with each other to achieve desired stability and dissolution for the patients' compliance. During the development study to combine montelukast and rupatadine, it has been found that montelukast shows stability and dissolution problems when it is used together with rupatadine in a conventional tablet formulation (one layer) or in capsule form. The analysis results that, the combination in conventional tablet or capsule form shows an increase in impurity and a decrease in dissolution of montelukast. Owing to the incompatibility problem of these active agents, in this invention bilayer tablet has been developed and desired dissolution and stability has been achieved. Dissolution results of the two active drug substances are given in below in Example 2, in more detail.
Thus, the bilayer tablet formulation of the present invention comprises 3.00 to 15.00 % by weight montelukast sodium as active drug substance in the first layer and comprises 5.00 to 20.00 % by weight rupatadine fumarate as active drug substance in the second layer.
In a further embodiment, the bilayer tablet formulation comprises at least one disintegrant.
According to this embodiment, the disintegrant is selected from the group comprising croscarmellose sodium, pregelatinized starch, crospovidone, sodium starch glycolate, low- substituted hydroxpropyl cellulose, polyvinylpyrrolidone (K - 30), hydroxylpropyl methyl cellulose, carboxy methyl cellulose calcium, sodium carboxy methyl cellulose, magnesium aluminum silica, sodium dodecyl sulphate, calcium silicate or mixtures thereof. Preferably, the disintegrant is croscarmellose sodium or pregelatinized starch or mixtures thereof. More preferably, the disintegrant is croscarmellose sodium in first layer and pregelatinized starch in second layer. Due to the use of different disintegrants separately in the layers, the efficient and desired dissolution of both active drug substances are achieved rapidly. Disintegrants give advantages to formulation in terms of binding strength to the layers. With the synergistic effect of disintegrants used in layers separately comprising active drug substances, layers adhere to each other and robust bilayer tablet with desired dissolution has been achieved. Disintegrants used in this present invention are croscarmellose sodium in first layer and pregelatinized starch in second layer.
According to this embodiment, the weight ratio (w/w) of croscarmellose sodium in first layer to pregelatinized starch in second layer is between 0.1 and 1 .0. Preferably, the weight ratio (w/w) is 0.5 - 0.7.
In one embodiment, the bilayer tablet of the present invention further comprises at least one excipient. According to this embodiment, the excipients are selected from the group comprising binders, fillers, lubricants and coloring agents or mixtures thereof.
Suitable binders may include but not limited to hydroxylpropyl cellulose (Klucel LF), hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, sugars, glycose syrups, natural gums, guar gum, tragachanti gum, gelatins, pullulan, agar, alginate, sodium algynates, glycyrrhizin, polymetacrylates, collagen, alginate, sodium alginate, hyaluronic acid, pectin, carrageenan, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, benthonite, laponite, cetostearyl alcohol, polyoxyethylene-alkyl ethers, acacia mucilage, polydextrose, polyethylene oxide, xylitol, sucrose stearate or mixtures thereof. Preferably the binder is hydroxylpropyl cellulose (Klucel LF).
Suitable fillers may include, but not limited to microcrystalline cellulose (pH 101 , pH 102), lactose monohydrate, starch, mannitol, dibasic calcium phosphate, tribasic calcium
di Lt jpaaneay
phosphate, trehalose, isomalt, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof. Preferably the filler is microcrystalline cellulose (pH 101).
Suitable lubricants may include but not limited to magnesium stearate, sodium stearyl fumarate, polyethylene glycol, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, polyethylene glycol, paraffin or mixtures thereof. Preferably, the lubricant is magnesium stearate.
Suitable coloring agents, may include but not limited to yellow iron oxide, Curcumin, Carmine, Indigo Carmine, Chlorophy II, Helindone pink CN, Diiodofluorescein or mixtures thereof. Preferably, the coloring agent is yellow iron oxide.
Example 1 :
1st layer % by weight
montelukast sodium 3.00-15.00
hydroxypropyl cellulose (Klucel LF) 1.00-5.00
Φ
re
—I microcrystalline cellulose (PH 101) 30.00-60.00
</)
re lactose monohydrate 30.00-60.00
3
O croscarmellose sodium 1.00-5.00
C
O
Έ magnesium stearate 0.10-2.00
pure water 30.00-50.00
montelukast Layer 50.00 - 65.00
2"a layer % by weight
rupatadine fumarate 5.00-20.00
prejelatinized starch 2.00-10.00
0)
microcrystalline cellulose (PH 101) 30.00-60.00
lactose monohydrate 30.00-60.00
yellow iron oxide 0.10-2.00
DC magnesium stearate 0.10-2.00
pure water 40.00-60.00
rupatadine layer 35.00-50.00
The production of the formulation is carried out as follows:
Montelukast Layer: montelukast sodium, hydroxypropyl cellulose (Klucel LF), microcrystalline cellulose (PH 101 ), lactose monohydrate and half amount of croscarmellose sodium are taken into container. Powder mixture is spray-granulated with pure water. The mixture is dried. The rest of the croscarmellose sodium is added to this mixture, and mixed. Then, magnesium stearate is added to this mixture and mixed. Rupatadine layer: rupatadine fumarate, prejelatinized starch, microcrystalline cellulose (PH 101 ), lactose monohydrate and yellow iron oxide are taken into collete and powder mixture is wet granulated with pure water. Then, the mixture is sieved and dried in fluid-bed dryer. Then, the mixture is sieved again. Magnesium stareate is added and mixed again. Two powder mixtures, are put into tableting machine separately to form bilayer tablets.
Example 2 (Dissolution profile test)
The bilayer tablet formulation of this present invention (Example 1 ), was tested by its dissolution profile in 0.5% solution of sodium dodecyl sulphate and at 37 <Ό using a USP apparatus II method in 900 ml_, rotating at 75 rpm against the reference product which is mentioned below as conventional (one layer) tablet or capsule form. The results are shown below in Table 1 . Table 1 : Dissolution profile test results (%)
Reference product* (in one layer tablet or in capsule form): montelukast sodium , rupatadine fumarate, hydroxpropyl cellulose (Klucel LF), microcrystalline cellulose (pH101 ), lactose monohydrate, croscarmellose sodium and magnesium stearate. (The amount of the ingredients are same with the amounts given in example 1 , in montelukast layer)
Therefore it is shown that, when these molecules are formulated together in one layer tablet form or in capsule form the dissolution and bioavailbilty of montelukast is significanti decreased. When they are formulated separately in a bilayer formulation the amounts are increased.
Claims
1 . A bilayer tablet formulation comprising montelukast sodium in first layer and rupatadine fumarate in second layer.
2. The bilayer tablet formulation according to claim 1 , wherein the first layer comprising 3.00 to 15.00 % by weight montelukast sodium as active drug substance and the second layer comprising 5.00 to 20.00 % by weight rupatadine fumarate as drug substance.
3. The bilayer tablet formulation according to claim 1 , further comprising at least one disintegrant.
4. The bilayer tablet formulation according to claim 3, wherein the disintegrant is selected from the group comprising croscarmellose sodium, pregelatinized starch, crospovidone, sodium starch glycolate, low-substituted hydroxpropyl cellulose, polyvinylpyrrolidone, hydroxylpropyl methyl cellulose, carboxy methyl cellulose calcium, sodium carboxy methyl cellulose, magnesium aluminum silica, sodium dodecyl sulphate, calcium silicate or mixtures thereof.
5. The bilayer tablet formulation according to claim 4, wherein the disintegrant is crosscarmellose sodium or pregelatinized starch or mixtures thereof.
6. The bilayer tablet formulation according to claim 5, wherein the disintegrant is crosscarmellose sodium in first layer and pregelatinized starch in second layer.
7. The bilayer tablet formulation according to claim 6, wherein the weight ratio (w/w) of croscarmellose sodium in first layer to pregelatinized starch in second layer is between 0.1 and 1 .0.
8. The bilayer tablet formulation according to any preceding claims, further comprising at least one excipient.
9. The bilayer tablet formulation according to claim 8, wherein the excipients are selected from the group comprising binders, fillers, lubricants and coloring agents or mixtures thereof.
10. The bilayer tablet formulation according to any preceding claims, comprising; a. 3.00 to 15.00 % of montelukast sodium
b. 1 .00 to 5.00 % of hydroxypropyl cellulose
c. 30.00 to 60.00 % of microcrystalline cellulose
d. 30.00 to 60.00 % of lactose monohydrate
e. 1 .00 to 5.00 % of croscarmellose sodium
f. 0.10 to 2.00 % of magnesium stearate
g. 30.00 to 50.00 % of pure water
in first layer and a. 5.00 to 20.00 % of rupatadine fumarate
b. 2.00 to 10.00 % of pregelatinized starch
h. 30.00 to 60.00 % of microcrystalline cellulose
i. 30.00 to 60.00 % of lactose monohydrate
j. 1 .00 to 5.00 % of croscarmellose sodium
k. 0.10 to 2.00 % of yellow iron oxide
I. 0.10 to 2.00 % of magnesium stearate
m. 40.00 to 60.00 % of pure water
in second layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17723019.0A EP3397284A1 (en) | 2016-04-22 | 2017-04-21 | Bilayer tablet formulations of montelukast and rupatadine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2016/05261 | 2016-04-22 | ||
| TR201605261 | 2016-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017182641A1 true WO2017182641A1 (en) | 2017-10-26 |
Family
ID=58701595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2017/059538 WO2017182641A1 (en) | 2016-04-22 | 2017-04-21 | Bilayer tablet formulations of montelukast and rupatadine |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3397284A1 (en) |
| WO (1) | WO2017182641A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024126772A1 (en) | 2022-12-15 | 2024-06-20 | Noucor Health, S.A. | Pharmaceutical composition comprising rupatadine and montelukast |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016173A1 (en) | 1995-11-02 | 1997-05-09 | Merck Frosst Canada Inc. | New technology for wet granulation |
| US6803468B2 (en) | 2000-08-29 | 2004-10-12 | Ranbaxy Laboratories Limited | Process for the synthesis of n-(5-methylnicontinoyl)-4 hydroxypiperidine, a key intermediate of rupatadine |
| WO2015069203A1 (en) * | 2013-11-06 | 2015-05-14 | Santa Farma Ilaç Sanayi A.Ş. | Capsule comprising rupatadine fumarate and montelukast sodium |
-
2017
- 2017-04-21 WO PCT/EP2017/059538 patent/WO2017182641A1/en active Application Filing
- 2017-04-21 EP EP17723019.0A patent/EP3397284A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016173A1 (en) | 1995-11-02 | 1997-05-09 | Merck Frosst Canada Inc. | New technology for wet granulation |
| US6803468B2 (en) | 2000-08-29 | 2004-10-12 | Ranbaxy Laboratories Limited | Process for the synthesis of n-(5-methylnicontinoyl)-4 hydroxypiperidine, a key intermediate of rupatadine |
| WO2015069203A1 (en) * | 2013-11-06 | 2015-05-14 | Santa Farma Ilaç Sanayi A.Ş. | Capsule comprising rupatadine fumarate and montelukast sodium |
Non-Patent Citations (3)
| Title |
|---|
| NIDHI NK ET AL: "ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF SIMULTANEOUS ESTIMATION OF RUPATADINE FUMARATE AND MONTELUKAST SODIUM BY RP-HPLC", 1 January 2014 (2014-01-01), pages 393 - 399, XP055380575, Retrieved from the Internet <URL:http://www.ijpra.com/File_Folder/393-399(ijpra).pdf> * |
| R PARIMALA ET AL: "DEVELOPMENT AND SIMULTANEOUS VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR THE ASSAY OF MONTELUKAST AND RUPATADINE IN SOLID DOSAGE FORM", INTERNATIONAL RESEARCH JOURNAL OF PHARMACY, vol. 3, no. 12, 1 December 2012 (2012-12-01), pages 91 - 96, XP055169800, ISSN: 2230-8407 * |
| VIVEKKUMAR K. REDASANI ET AL: "Stability indicating RP-HPLC method for simultaneous estimation of rupatadine fumarate and montelukast sodium in bulk and tablet dosage form", JOURNAL OF ANALYTICAL CHEMISTRY, vol. 69, no. 4, 26 March 2014 (2014-03-26), pages 384 - 389, XP055169763, ISSN: 1061-9348, DOI: 10.1134/S1061934814040121 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024126772A1 (en) | 2022-12-15 | 2024-06-20 | Noucor Health, S.A. | Pharmaceutical composition comprising rupatadine and montelukast |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3397284A1 (en) | 2018-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102006000B1 (en) | Capsule formulation comprising montelukast or a pharmaceutically acceptable salt thereof, and levocetirizine or a pharmaceutically acceptable salt thereof | |
| JP6245677B2 (en) | Orally disintegrating tablets | |
| TWI565482B (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| WO2012064301A2 (en) | Physically improved tablet formulations | |
| WO2011110939A2 (en) | Pharmaceutical compositions of substituted benzhydrylpiperazines | |
| DK3294719T3 (en) | VORTIOXETIN-pyroglutamate | |
| JP2018177815A (en) | Escitalopram pharmaceutical composition | |
| TW201106991A (en) | Tablets | |
| JP2018535991A (en) | Pharmaceutical composition containing dravirin, tenofovir disoproxil fumarate and lamivudine | |
| US20160008375A1 (en) | Pharmaceutical formulations comprising quetiapine and escitalopram | |
| JP2018530566A (en) | 8-[(3R) -3-Amino-1-piperidinyl] -7- (2-butyn-1-yl) -3,7-dihydro-3-methyl-1- [4-methyl-2-quinazolinyl) methyl ] -1H-purine-2,6-dione or a pharmaceutical composition containing a pharmaceutically acceptable salt thereof | |
| TW202200123A (en) | Pharmaceutical composition with complex and preparation method therefor having a complex of an angiotensin II receptor antagonist metabolite and an NEP inhibitor | |
| WO2017182641A1 (en) | Bilayer tablet formulations of montelukast and rupatadine | |
| TWI574690B (en) | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation | |
| TWI488658B (en) | Method for improvement of elution | |
| TWI414310B (en) | Elution-improved pharmaceutical preparation | |
| EP3397285A1 (en) | Tablet formulations of montelukast sodium and rupatadine fumarate | |
| EP2949321A1 (en) | Multilayer formulations of fexofenadine and montelukast | |
| WO2019230937A1 (en) | Solid oral dosage form having excellent dissolution properties | |
| JP6498158B2 (en) | Orally disintegrating tablets | |
| KR20210071242A (en) | Pharmaceutical composition | |
| WO2013077829A1 (en) | Water-soluble pharmaceutical granules | |
| JP2020147542A (en) | Multilayer tablet comprising dabigatran etexilate or pharmaceutically acceptable salt thereof | |
| JP2011153135A (en) | Taltirelin preparation and method for maintaining elution properties of taltirelin preparation | |
| BR102013004720B1 (en) | STABLE PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARING A PHARMACEUTICAL COMPOSITION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 2017723019 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2017723019 Country of ref document: EP Effective date: 20180802 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |